| P/E (FY) | 2.8 | Sales (TTM) | $2.0M |
| Earnings (TTM) | $110.0M | ROE | 37.02% |
| Net Margin | 3202.50% | ROIC | −10.48% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −9.55% |
| Market Cap | $170.7M | Trading Days | 4838 |
| 52W High | 5.19 |
| 52W Low | 1.98 |
| % Off High | −19.65% |
| YTD | 56.95% | 1Y | 102.40% |
| 3Y | 36.37% | 5Y | −67.61% |
| 10Y | −44.37% | Since incept. (ann.) | −2.93% |
| Ann. Volatility (1Y) | 54.39% | Ann. Volatility (3Y) | 54.99% |
| Sharpe (1Y) | 1.58 | Sharpe (3Y) | 0.52 |
| Max Drawdown (1Y) | −23.89% | Max Drawdown (3Y) | −50.43% |
| Beta (3Y, vs SPY) | 1.28 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $168.2M | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $165.3M | — |
| HELP | CYBIN INC. | $164.6M | — |
| ANTX | AN2 Therapeutics, Inc. | $177.6M | — |
| CAMP | Camp4 Therapeutics Corp | $177.6M | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $163.7M | — |
| OKUR | OnKure Therapeutics, Inc. | $163.6M | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $162.8M | — |
| NKTX | Nkarta, Inc. | $161.7M | — |
| KPTI | Karyopharm Therapeutics Inc. | $160.7M | — |
| WHWK | Whitehawk Therapeutics, Inc. |
| $183.0M |
| — |
| PYXS | Pyxis Oncology, Inc. | $184.4M | — |
